Kiniksa Pharmaceuticals International plc. - Class A

Research Kiniksa Pharmaceuticals International plc. - Class A (KNSA) on Bullrun: valuation model: 27.7% overvalued, market cap USD 4.80B, P/E 68.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKNSA
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal27.7% overvalued
• Market capUSD 4.80B
• P/E68.8
• Financial periodFY2025
• RevenueUSD 677.56M
• Revenue growth60.1%
• Net incomeUSD 59.01M
• Free cash flowUSD 136.42M
• Gross margin88.5%

Valuation Snapshot

Bullrun's latest valuation model marks Kiniksa Pharmaceuticals International plc. - Class A as 27.7% overvalued; latest market cap is USD 4.80B; P/E is 68.8.

Company Brief

Kiniksa reported a 60.1% year-over-year revenue increase and achieved profitability with net income up 236.6%. The company is also advancing its pipeline by presenting upcoming data from clinical trials at investor conferences.

Revenue grew significantly to reach FY2025 levels, supported by gross margins expanding to 88.5% while the company transitioned into a profitable net income position.

Investors should monitor sales performance of ARCALYST and potential regulatory developments for KPL-387's Phase 2/3 trials.

Frequently asked questions

Is Kiniksa Pharmaceuticals International plc. - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Kiniksa Pharmaceuticals International plc. - Class A as 27.7% overvalued.

What is Kiniksa Pharmaceuticals International plc. - Class A's market cap?

Kiniksa Pharmaceuticals International plc. - Class A's market capitalization is USD 4.80B.

What is Kiniksa Pharmaceuticals International plc. - Class A's P/E ratio?

Kiniksa Pharmaceuticals International plc. - Class A's price-to-earnings (P/E) ratio is 68.8.

What does Kiniksa Pharmaceuticals International plc. - Class A do?

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.